191 related articles for article (PubMed ID: 33152842)
21. Radiotherapy for early-stage primary ocular adnexal mucosa-associated lymphoid tissue lymphoma.
Ohga S; Nakamura K; Shioyama Y; Sasaki T; Yoshitake T; Atsumi K; Terashima K; Asai K; Matsumoto K; Yoshikawa H; Kawano Y; Honda H
Anticancer Res; 2013 Dec; 33(12):5575-8. PubMed ID: 24324100
[TBL] [Abstract][Full Text] [Related]
22. Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa.
Annibali O; Chiodi F; Sarlo C; Cortes M; Quaranta-Leoni FM; Quattrocchi C; Bianchi A; Bonini S; Avvisati G
Biomed Res Int; 2015; 2015():895105. PubMed ID: 26425558
[TBL] [Abstract][Full Text] [Related]
23. Favourable response to rituximab by an ocular adnexal primary lymphoma.
Luque Valentin-Fernandez ML; Alvarez Rodríguez F; Rodríguez Jiménez I
Arch Soc Esp Oftalmol; 2016 Nov; 91(11):539-542. PubMed ID: 27125186
[TBL] [Abstract][Full Text] [Related]
24. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
Ferreri AJ; Govi S; Colucci A; Crocchiolo R; Modorati G
Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
[TBL] [Abstract][Full Text] [Related]
25. Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients.
Tanimoto K; Kaneko A; Suzuki S; Sekiguchi N; Watanabe T; Kobayashi Y; Kagami Y; Maeshima AM; Matsuno Y; Tobinai K
Jpn J Clin Oncol; 2007 May; 37(5):337-44. PubMed ID: 17562719
[TBL] [Abstract][Full Text] [Related]
26. Clinical features and treatment outcomes of primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: a single center retrospective analysis of 64 patients in China.
Yu H; Du YX; Sun ZC; Fu XR; Tan N; Gong WF; Zhang MZ
Int J Ophthalmol; 2019; 12(11):1731-1736. PubMed ID: 31741862
[TBL] [Abstract][Full Text] [Related]
27. Rituximab immunotherapy for ocular adnexal lymphoma: clinicopathologic correlation with 5-year follow-up.
Sokol JA; Landau L; Lauer SA
Ophthalmic Plast Reconstr Surg; 2009; 25(4):322-4. PubMed ID: 19617799
[TBL] [Abstract][Full Text] [Related]
28. Intralesional rituximab in primary conjunctival follicular lymphoma relapsed.
Rodríguez Villa S; Ruiz Rodríguez MJ; Vargas Pabón M
Arch Soc Esp Oftalmol; 2017 Jul; 92(7):326-329. PubMed ID: 27986437
[TBL] [Abstract][Full Text] [Related]
29. MALT lymphoma of the lacrimal gland in the context of systemic lupus erythematosus: complete remission after treatment with rituximab.
Tektonidou MG
Lupus; 2010 Sep; 19(10):1243-5. PubMed ID: 20501524
[TBL] [Abstract][Full Text] [Related]
30. Immunoglobulin G4 (IgG4)-Positive Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma and Idiopathic Orbital Inflammation.
Sohn EJ; Ahn HB; Roh MS; Jung WJ; Ryu WY; Kwon YH
Ophthalmic Plast Reconstr Surg; 2018; 34(4):313-319. PubMed ID: 28749851
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lymphoma: a pilot study.
Savino G; Battendieri R; Balia L; Colucci D; Larocca LM; Laurenti L; De Padua L; Blasi MA; Balestrazzi E
Cancer Sci; 2011 Aug; 102(8):1565-7. PubMed ID: 21564418
[TBL] [Abstract][Full Text] [Related]
32. Effects of radiation therapy on the meibomian glands and dry eye in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma.
Kim SE; Yang HJ; Yang SW
BMC Ophthalmol; 2020 Jan; 20(1):24. PubMed ID: 31931766
[TBL] [Abstract][Full Text] [Related]
33. Relapse in patients with limited-stage ocular adnexal lymphoma treated by chemoimmunotherapy: Extended follow-up of a phase 2 study.
Kim SY; Lee WS; Oh SY; Yang DH; Kim HJ; Park SK; Yang JW; Yang SW; Cho SG
Cancer Med; 2022 Jul; 11(14):2817-2823. PubMed ID: 35277938
[TBL] [Abstract][Full Text] [Related]
34. [Lymphoproliferative lesions of the ocular adnexa. Differential diagnostic guidelines].
Coupland SE
Ophthalmologe; 2004 Feb; 101(2):197-215; quiz 216-7. PubMed ID: 15046030
[TBL] [Abstract][Full Text] [Related]
35. Intralesional interferon-α for conjunctival mucosa-associated lymphoid tissue lymphoma: long-term results.
Blasi MA; Tiberti AC; Valente P; Laguardia M; Sammarco MG; Balestrazzi A; Larocca LM; Balestrazzi E
Ophthalmology; 2012 Mar; 119(3):494-500. PubMed ID: 22226154
[TBL] [Abstract][Full Text] [Related]
36. Review article: Mucosa-associated lymphoid tissue (MALT)-type lymphoma of ocular adnexa. Biology and treatment.
Annibali O; Sabatino F; Mantelli F; Olimpieri OM; Bonini S; Avvisati G
Crit Rev Oncol Hematol; 2016 Apr; 100():37-45. PubMed ID: 26857986
[TBL] [Abstract][Full Text] [Related]
37. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa.
Ferreri AJ; Ponzoni M; Martinelli G; Muti G; Guidoboni M; Dolcetti R; Doglioni C
Haematologica; 2005 Nov; 90(11):1578-9. PubMed ID: 16266908
[TBL] [Abstract][Full Text] [Related]
38. Intralesional or intraorbital rituximab injection for the management of biopsy-proven idiopathic orbital inflammation involving the lacrimal gland.
Demirci H; Ciftci S; Teo HMT; Demirci FY; Shinder R; Elner VM
Can J Ophthalmol; 2023 Nov; ():. PubMed ID: 37995759
[TBL] [Abstract][Full Text] [Related]
39. [Clinical analysis of ocular adnexal MALT lymphoma].
Xu WW; Zhang MN; Wei RL
Zhonghua Yan Ke Za Zhi; 2010 Apr; 46(4):299-303. PubMed ID: 20654054
[TBL] [Abstract][Full Text] [Related]
40. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
